Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-001928-17
    Sponsor's Protocol Code Number:GCT1046-04
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2021-11-10
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-001928-17
    A.3Full title of the trial
    A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment With Standard of Care Therapy With an Immune Checkpoint Inhibitor
    Studio di fase 2, multicentrico, randomizzato, in aperto su GEN1046 in monoterapia e in combinazione con terapia antitumorale in soggetti con carcinoma polmonare non a piccole cellule metastatico recidivante/refrattario in seguito a trattamento con terapia di cura standard con un inibitore del checkpoint immunitario
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Safety and Efficacy Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Recurrent Non-Small Cell Lung cancer
    Studio di sicurezza ed efficacia su GEN1046 in monoterapia e in combinazione con terapia antitumorale in soggetti con carcinoma polmonare non a piccole cellule ricorrente
    A.3.2Name or abbreviated title of the trial where available
    A Safety and Efficacy Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in
    Studio di sicurezza ed efficacia su GEN1046 in monoterapia e in combinazione con terapia antitumoral
    A.4.1Sponsor's protocol code numberGCT1046-04
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGENMAB A/S
    B.1.3.4CountryDenmark
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing support
    B.4.2Country
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGenmab A/S
    B.5.2Functional name of contact pointClinical Trial Information
    B.5.3 Address:
    B.5.3.1Street AddressKalvebod Brygge 43
    B.5.3.2Town/ cityCopenhagen V
    B.5.3.3Post code1560
    B.5.3.4CountryDenmark
    B.5.4Telephone number+4570202728
    B.5.6E-mailclinicaltrials@genmab.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name KEYTRUDA 25 mg/mL concentrate for solution for infusion
    D.2.1.1.2Name of the Marketing Authorisation holderMerck Sharp & Dohme B.V.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameKeytruda
    D.3.2Product code [Keytruda]
    D.3.4Pharmaceutical form Concentrate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPembrolizumab
    D.3.9.1CAS number 1374853-91-4
    D.3.9.2Current sponsor codeKeytruda
    D.3.9.4EV Substance CodeSUB167136
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDuoBody-PD-L1x4-1BB
    D.3.2Product code [GEN1046]
    D.3.4Pharmaceutical form Concentrate for solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 2253937-12-9
    D.3.9.2Current sponsor codeGEN1046-DS
    D.3.9.3Other descriptive nameBisG1, anti-(human Cluster of Differentiation 274) (human 7717b gamma1-chain), disulfide with human 7717b lambda-chain, dimer / Immunoglobulin G1, anti-(human Cluster of Differentiation 137) (human 7729a gamma1-chain), disulfide with human 7729a kappa-chain, dimer
    D.3.9.4EV Substance CodeSUB195353
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Malignant Solid Tumors - Non Small Cell Lung Cancer
    Tumori solidi maligni - Cancro del polmone non a piccole cellule
    E.1.1.1Medical condition in easily understood language
    Locally advanced or metastatic non-small cell lung cancer in patients who failed a first line of treatment.
    Carcinoma polmonare non a piccole cellule localmente avanzato o metastatico in pazienti che hanno fallito una prima linea di trattamento.
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level PT
    E.1.2Classification code 10061873
    E.1.2Term Non-small cell lung cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluate the anti-tumor activity of GEN1046 as monotherapy and in combination with anti-cancer therapy in subjects with relapsed/refractory metastatic NSCLC
    Valutare l'attività antitumorale di GEN1046 in monoterapia e in combinazione con terapia antitumorale in soggetti con NSCLC metastatico recidivante/refrattario
    E.2.2Secondary objectives of the trial
    • Evaluate time to onset and durability of the anti-tumor response of GEN1046 as monotherapy and in combination with anti-cancer therapy
    in subjects with relapsed/refractory metastatic NSCLC
    • Evaluate the clinical benefit of GEN1046 as monotherapy and in combination with anti-cancer therapy
    • Assess safety and tolerability of GEN1046 as monotherapy and in combination with anti-cancer therapy
    • Valutare il tempo all'insorgenza e la durata della risposta antitumorale di GEN1046 in monoterapia e in combinazione con terapia antitumorale in soggetti con NSCLC metastatico recidivante/refrattario
    • Valutare il beneficio clinico di GEN1046 in monoterapia e in combinazione con terapia antitumorale
    • Valutare la sicurezza e la tollerabilità di GEN1046 in monoterapia e in combinazione con terapia antitumorale
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Subject must sign an informed consent form (ICF).
    2. Subject must be at least 18 years of age.
    3. Subject has histologically or cytologically confirmed diagnosis of stage 4 NSCLC with at least 1 prior line of systemic therapy containing an anti-PD-1/PD-L1 mAb for metastatic disease.
    4. Subject must have PD-L1 tumor expression score of TPS >/=1%assessed by a central laboratory during screening.
    5. Subject must have measurable disease per RECIST v1.1. as assessed by the investigator.
    6. Subject must have Eastern Cooperative Oncology Group (ECOG) performance status (PS) </=1.
    7. Subject must have life expectancy of at least 3 months.
    8. Subject must have adequate organ and bone marrow function as defined in protocol.
    1.Il soggetto deve firmare un modulo di consenso informato (ICF).
    2.Il soggetto deve avere un'età pari o superiore a 18 anni.
    3.Il soggetto presenta una diagnosi confermata istologicamente o citologicamente di NSCLC di stadio 4 con almeno 1 linea precedente di terapia sistemica contenente un anticorpo monoclonale (mAb) anti-PD-1/PD-L1 per la malattia metastatica.
    4.Il soggetto deve avere un'espressione di PD-L1 nel tumore con un punteggio di proporzione tumorale (TPS) >/=1% valutato da un laboratorio centrale durante lo screening.
    5.Il soggetto deve avere una malattia misurabile secondo i criteri RECIST v1.1 valutati dallo sperimentatore.
    6.Il soggetto deve avere ECOG PS </=1.
    7.Il soggetto deve avere un'aspettativa di vita di almeno 3 mesi.
    8.Il soggetto deve presentare un'adeguata funzionalità d’organo e di midollo osseo come descritto nel protocollo.
    E.4Principal exclusion criteria
    1. Documentation of known EGFR, ROS1, or ALK mutations or gene rearrangements. Additionally, the statues of BRAF, METex 14 skipping, KRAS mutations, RET rearrangement, high-level MET amplification, or NTRK gene infusions will be required.
    2. Subject has been exposed to any of the following therapies:
    - Treatment with an anti-cancer agent within 28 days prior to GEN1046 administration.
    - Any investigational agent for the treatment of stage 4 NSCLC.
    - Radiotherapy within 14 days prior to first GEN1046 administration. Radiotherapy within 14 days prior to first GEN1046 administration or received lung radiation therapy of >30 Gy within 6 months of the first dose of trial treatment. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis.
    - Chronic systemic immunosuppressive corticosteroid doses, ie, prednisone >10 mg daily or a cumulative dose >150 mg prednisone within 14 days before the first GEN1046 administration.
    3. Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any
    of its excipients.
    4. Subject has a history of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
    5. Subject has any of the following:
    - Ongoing or active infection requiring intravenous treatment with antiinfective therapy that has been administered <2 weeks prior to first dose.
    - Symptomatic congestive heart failure (grade III or IV as classified by the New York Heart Association), unstable angina pectoris, or cardiac arrhythmia.
    - Uncontrolled hypertension defined as systolic blood pressure =160 mmHg and/or diastolic blood pressure =100 mmHg, despite optimal medical management.
    - Ongoing or recent (within 6 months) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments, which may suggest risk for irAEs.
    6. Subject has a known history of any of the following:
    - Grade 3 or higher irAEs that led to treatment discontinuation of a prior immunotherapy treatment.
    - Myositis, Guillain-Barré syndrome, or myasthenia gravis of any grade.
    - Liver disease (eg, alcoholic hepatitis or non-alcoholic steatohepatitis,
    drug-related or autoimmune hepatitis, or evidence of hepatic cirrhosis).
    - Organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within 3 months prior to the first dose of GEN1046.
    - Grade 3 or higher allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.
    For further information, please refer to Clinical Trial Protocol.
    1. Documentazione di mutazioni o riarrangiamenti genici EGFR, ROS1 o ALK noti. Inoltre, saranno richiesti gli statuti di BRAF, METex 14 skipping, mutazioni KRAS, riarrangiamento RET, amplificazione MET ad alto livello, o infusioni del gene NTRK.
    2. Il soggetto è stato esposto a una delle seguenti terapie:
    - Trattamento con un agente anti-cancro entro 28 giorni prima della somministrazione di GEN1046.
    - Qualsiasi agente sperimentale per il trattamento del NSCLC al quarto stadio.
    - Radioterapia entro 14 giorni prima della prima somministrazione di GEN1046. Radioterapia entro 14 giorni prima della prima somministrazione di GEN1046 o se hanno ricevuto una radioterapia polmonare di >30 Gy entro 6 mesi dalla prima dose di trattamento dello studio. I soggetti devono essersi ripresi da tutte le tossicità legate alle radiazioni, non devono richiedere corticosteroidi e non devono aver avuto una polmonite da radiazioni.
    - Dosi sistemiche croniche di corticosteroidi immunosoppressivi, cioè prednisone >10 mg al giorno o una dose cumulativa >150 mg di prednisone
    entro 14 giorni prima della prima somministrazione di GEN1046.
    3. Il soggetto ha una grave ipersensibilità (=Grado 3) a pembrolizumab e/o a qualsiasi
    dei suoi eccipienti.
    4. Il soggetto ha una storia di polmonite (non infettiva) / malattia polmonare interstiziale che ha richiesto steroidi o ha attualmente una polmonite / malattia polmonare interstiziale.
    5. Il soggetto ha una delle seguenti condizioni:
    - Infezione in corso o attiva che richiede un trattamento endovenoso con terapia antinfettiva che è stata somministrata <2 settimane prima della prima
    dose.
    - Insufficienza cardiaca congestizia sintomatica (grado III o IV secondo la classificazione della New York Heart Association), angina pectoris instabile o aritmia cardiaca.
    aritmia cardiaca.
    - Ipertensione non controllata definita come pressione sanguigna sistolica =160 mmHg e/o pressione sanguigna diastolica =100 mmHg, nonostante una gestione medica ottimale.
    gestione medica ottimale.
    - . Evidenza in corso o recente (entro 6 mesi) di una significativa malattia autoimmune che ha richiesto un trattamento con trattamenti immunosoppressivi sistemici, che può suggerire il rischio di irAEs.
    6. Il soggetto ha un'anamnesi nota di uno dei seguenti casi
    - IrAEs di grado 3 o superiore che hanno portato all'interruzione di un precedente trattamento di immunoterapia.
    - Miosite, sindrome di Guillain-Barré o miastenia gravis di qualsiasi grado.
    - Malattia epatica (es. epatite alcolica o steatoepatite non alcolica, epatite correlata a farmaci o autoimmune, o evidenza di cirrosi epatica).
    - Allotrapianto d'organo (eccetto il trapianto di cornea) o trapianto di midollo osseo autologo o allogenico, o salvataggio di cellule staminali entro 3 mesi
    prima della prima dose di GEN1046.
    - Reazioni allergiche di grado 3 o superiore alla terapia con anticorpi monoclonali, nonché allergia o intolleranza nota o sospetta a qualsiasi agente somministrato nel corso di questo studio.
    Per ulteriori informazioni, si prega di fare riferimento al protocollo dello studio clinico.
    E.5 End points
    E.5.1Primary end point(s)
    Objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by investigator
    Tasso di risposta obiettiva (ORR) secondo Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 valutato dallo sperimentatore
    E.5.1.1Timepoint(s) of evaluation of this end point
    ORR is defined as the proportion of subjects with a confirmed response of partial response (PR)
    or complete response (CR) according to RECIST v1.1 criteria. The minimum time from first infusion of trial drug required to qualify for an assessment of stable disease (SD) is 5 weeks, corresponding to the minimum planned time of the first imaging assessment.
    Disease will be evaluated per RECIST v1.1. CT with contrast (preferred) or MRI will be obtained at baseline before the first dose and 6, 12, 18, and 24 weeks (±7 days) after the first dose of trial medication, and thereafter, every 9 weeks (±7 days). CT or MRI will continue to be obtained until disease progression, start of subsequent anti-cancer therapy, withdrawal of consent, or death, whichever occurs first.
    L'ORR è definito come la proporzione di sogg.con risposta confermata di risp.parziale(PR)o completa(CR)2o i criteri RECISTv1.1.Il tempo minimo dalla prima infusione del farmaco richiesto per qualificarsi per una valutazione della malattia stabile(SD)è di 5 sett., cioè il tempo minimo previsto della prima valutazione di imaging.
    La malattia sarà valutata secondo RECIST v1.1.La TAC con contrasto(preferita)o risonanza magnetica saranno ottenute al basale prima della prima dose e a 6, 12, 18 e 24 settimane (±7gg) dopo la prima dose di farmaco, e poi, ogni 9 sett.(±7gg).La TAC o la risonanza magnetica continueranno ad essere ottenute fino alla progressione della malattia, all'inizio della successiva terapia antitumorale,al ritiro del consenso o al decesso,a 2a di ciò che si verifica per primo.
    E.5.2Secondary end point(s)
    • Duration of response (DOR) per RECIST v1.1
    • Time to response (TTR) per RECIST v1.1
    • Progression-free survival (PFS) per RECIST v1.1
    • Overall survival (OS)
    • Incidence and severity of AEs
    • Incidence and severity of laboratory abnormalities
    • Durata della risposta (DOR) secondo RECIST v1.1
    • Tempo alla risposta (TTR) secondo RECIST v1.1
    • Sopravvivenza libera da progressione (PFS) secondo RECIST v1.1
    • Sopravvivenza globale (OS)
    • Incidenza e gravità degli eventi avversi (EA)
    • Incidenza e gravità delle anomalie di laboratorio
    E.5.2.1Timepoint(s) of evaluation of this end point
    - DOR: DOR is defined for responders as the time from initial onset of
    response to first progression event, defined as radiographic progression
    or death.
    - TTR: Time to response (TTR) is defined as the time from first infusion
    of trial drug to onset of response.
    - PFS: PFS is defined as the time from first infusion of trial drug to first
    progression event, defined as radiographic progression or death.
    - OS: OS is defined as time from first infusion of trial drug to death due
    to any cause.
    - Safety, including AEs, physical examinations, Eastern Cooperative
    Oncology Group (ECOG)performance status (PS), vital signs,
    electrocardiograms, and laboratory values, will be monitored throughout
    the trial.
    - DOR:DOR è definito per i rispondenti come il tempo dall'inizio della risposta al primo evento di progressione, definito come progressione radiografica
    o decesso.
    - TTR:Il tempo di risposta (TTR) è definito come il tempo dalla prima infusione del farmaco dello studio alla comparsa della risposta.
    - PFS:la PFS è definita come il tempo trascorso tra la prima infusione del farmaco in studio e il primo evento di progressione, definito come progressione radiografica o morte.
    - OS:OS è definita come il tempo che intercorre tra la prima infusione del farmaco in studio e la morte per qualsiasi causa.
    - Sicurezza,inclusi AE,esami fisici,Eastern Cooperative Oncology Group(ECOG)performance status(PS),segni vitali,elettrocardiogrammi e valori di lab,saranno monitorati durante
    la sperimentazione.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability, Immunogenicity, Biomarker Analyses, Health-related Quality of life
    Tollerabilità, immunogenicità, analisi dei biomarcatori, qualità della vita legata alla salute
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA41
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    France
    Germany
    Italy
    Netherlands
    Poland
    Portugal
    Spain
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The trial is considered completed when the last subject dies or withdraws from the trial. However, maximal trial duration is up to 3 years after the last subject's first treatment.
    La sperimentazione è considerata completata quando l'ultimo soggetto muore o si si ritira dalla sperimentazione. Tuttavia, la durata massima della sperimentazione è fino a 3 anni dopo il primo trattamento dell'ultimo soggetto.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 66
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 66
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    If the subject (or representative) is unable to read/write, an impartial witness should be present for the entire informed consent process and should personally date and sign ICF after the oral consent of the subject (or representative) is obtained.
    Se il soggetto (o il rappresentante) non è in grado di leggere/scrivere, un testimone imparziale dovrebbe essere presente per l'intero processo di consenso informato e dovrebbe datare e firmare personalmente l'ICF dopo che il consenso orale del sogge
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state70
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 99
    F.4.2.2In the whole clinical trial 132
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The sponsor will make their best effort to provide post-trial access to GEN1046 for those subjects with a potential treatment benefit, in maccordance with local laws and requirements.
    For subjects in Arms B and C, the continued access to trial treatment will end when a criterion for discontinuation is met or 35 (for Q3W dosing) /18 (for Q6W dosing) doses of pembrolizumab have been administered.
    Lo sponsor farà del suo meglio per fornire l'accesso post-trial a GEN1046 per quei soggetti con un potenziale beneficio di trattamento, in accordo con le leggi e i requisiti locali.
    Per i soggetti nei bracci B e C, l'accesso continuato al trattamento dello studio terminerà quando sarà soddisfatto un criterio di interruzione o saranno state somministrate 35 (per il dosaggio Q3W) / 18 (per il dosaggio Q6W) dosi di pembrolizumab.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-01-11
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-11-16
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 14:20:59 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA